目的建立角蛋白I型细胞骨架10[keratin type I cytoskeletal 10,KRT10)和VI型胶原蛋白A3[collagen alpha-3(VI)chain,COL6A3]短肽抗体的ELISA检测方法,并探讨两种瓜氨酸化短肽抗体在类风湿关节炎(rheumatoid arthritis,RA)实验室诊断中...目的建立角蛋白I型细胞骨架10[keratin type I cytoskeletal 10,KRT10)和VI型胶原蛋白A3[collagen alpha-3(VI)chain,COL6A3]短肽抗体的ELISA检测方法,并探讨两种瓜氨酸化短肽抗体在类风湿关节炎(rheumatoid arthritis,RA)实验室诊断中的价值。方法以合成短肽为包被抗原,抗人IgA,IgG及IgM为二抗,检测100例抗瓜氨酸化蛋白抗体(anti-citrullinated protein antibodies,ACPA)阳性组、100例健康对照组和29例RA确诊患者血清中的KRT10,KRT10_C,COL6A3及COL6A3_C短肽抗体水平,比较不同短肽抗体与RA的相关性,采用ROC曲线分析KRT10_C和COL6A3_C短肽抗体对于RA的诊断价值,并对此ELISA方法进行精密度评价。结果与临床诊断相比,KRT10_C短肽抗体诊断RA的灵敏度为58.62%,特异度为52.17%,用于诊断抗CCP抗体阳性RA患者的ROC曲线下面积达0.895;COL6A3_C短肽抗体诊断RA的灵敏度为65.52%,特异度为78.95%,用于诊断抗CCP抗体阴性的RA患者的ROC曲线下面积可达0.956。ELISA检测值KRT10_C(以抗人IgG为二抗)的批内变异系数分别为11.2%(低值)、7.8%(中值)和6.7%(高值)。ELISA检测COL6A3_C(以抗人IgM为二抗)的批内变异系数分别为12.9%(低值)、8.4%(中值)和8.9%(高值)。结论KRT10_C和COL6A3_C短肽抗体对RA诊断具有重要意义,有望加入并完善实验室诊断体系,提高RA的早期诊断率。展开更多
Keratins and corneous proteins are key components of biomaterials used in a wide range of applications and are potential substitutes for petrochemical-based products. Horns, hooves, feathers, claws, and similar animal...Keratins and corneous proteins are key components of biomaterials used in a wide range of applications and are potential substitutes for petrochemical-based products. Horns, hooves, feathers, claws, and similar animal tissues are abundant sources of α-keratin and corneous β-proteins, which are by-products of the food industry. Their close association with the meat industry raises environmental and ethical concerns regarding their disposal. To promote an eco-friendly and circular use of these materials in novel applications, efforts have focused on recovering these residues to develop sustainable, non-animal-related, affordable, and scalable procedures. Here, we review and examine biotechnological methods for extracting and expressing α-keratins and corneous β-proteins in microorganisms. This review highlights consolidated research trends in biomaterials, medical devices, food supplements, and packaging, demonstrating the keratin industry's potential to create innovative value-added products. Additionally, it analyzes the state of the art of related intellectual property and market size to underscore the potential within a circular bioeconomic model.展开更多
文摘目的建立角蛋白I型细胞骨架10[keratin type I cytoskeletal 10,KRT10)和VI型胶原蛋白A3[collagen alpha-3(VI)chain,COL6A3]短肽抗体的ELISA检测方法,并探讨两种瓜氨酸化短肽抗体在类风湿关节炎(rheumatoid arthritis,RA)实验室诊断中的价值。方法以合成短肽为包被抗原,抗人IgA,IgG及IgM为二抗,检测100例抗瓜氨酸化蛋白抗体(anti-citrullinated protein antibodies,ACPA)阳性组、100例健康对照组和29例RA确诊患者血清中的KRT10,KRT10_C,COL6A3及COL6A3_C短肽抗体水平,比较不同短肽抗体与RA的相关性,采用ROC曲线分析KRT10_C和COL6A3_C短肽抗体对于RA的诊断价值,并对此ELISA方法进行精密度评价。结果与临床诊断相比,KRT10_C短肽抗体诊断RA的灵敏度为58.62%,特异度为52.17%,用于诊断抗CCP抗体阳性RA患者的ROC曲线下面积达0.895;COL6A3_C短肽抗体诊断RA的灵敏度为65.52%,特异度为78.95%,用于诊断抗CCP抗体阴性的RA患者的ROC曲线下面积可达0.956。ELISA检测值KRT10_C(以抗人IgG为二抗)的批内变异系数分别为11.2%(低值)、7.8%(中值)和6.7%(高值)。ELISA检测COL6A3_C(以抗人IgM为二抗)的批内变异系数分别为12.9%(低值)、8.4%(中值)和8.9%(高值)。结论KRT10_C和COL6A3_C短肽抗体对RA诊断具有重要意义,有望加入并完善实验室诊断体系,提高RA的早期诊断率。
基金European Union's Horizon Europe research and innovation programme under grant agreement No.101060607for the research and innovation programme under grant agreement No.101037796+1 种基金National Recovery and Resilience Plan(NRRP),Mission 4.Component 2 Investment 1.3-Call for proposals No.341 of March 15,2022 of Italian Ministry of University and Research funded by the European Union-NextGenerationEUAward Number:Project code PE00000003,Concession Decree No.1550 of October 11,2022 adopted by the Italian Ministry of University and Research,CUP H93C22000630001,Project title“ON Foods-Research and innovation network on food and nutrition Sustainability,Safety and Security-Working ON Foods”.
文摘Keratins and corneous proteins are key components of biomaterials used in a wide range of applications and are potential substitutes for petrochemical-based products. Horns, hooves, feathers, claws, and similar animal tissues are abundant sources of α-keratin and corneous β-proteins, which are by-products of the food industry. Their close association with the meat industry raises environmental and ethical concerns regarding their disposal. To promote an eco-friendly and circular use of these materials in novel applications, efforts have focused on recovering these residues to develop sustainable, non-animal-related, affordable, and scalable procedures. Here, we review and examine biotechnological methods for extracting and expressing α-keratins and corneous β-proteins in microorganisms. This review highlights consolidated research trends in biomaterials, medical devices, food supplements, and packaging, demonstrating the keratin industry's potential to create innovative value-added products. Additionally, it analyzes the state of the art of related intellectual property and market size to underscore the potential within a circular bioeconomic model.
